Patent application number | Description | Published |
20090003920 | PERSONAL CARE PRODUCT HAVING A SOLID PERSONAL CARE COMPOSITION WITHIN A STRUCTURE MAINTAINING DISPENSER - A personal care product is disclosed comprising a personal care composition and a dispensing container having the personal care composition disposed therein. The personal care composition may have a pre-dispense G′ of at least about 5,000 Pa. The personal care product provides a G′ preservation percentage of no less than 10%. The dispensing container may comprise a container body having a storage void containing the personal care composition, a movable partition at least partially disposed within the storage void, a drive mechanism connected to and able to advance the movable partition, and a dispensing plate joined to the container body. The dispensing plate has an orifice through which the personal care composition is dispensed. The orifice may have an inscribed circle diameter of about 1 mm to about 12 mm. | 01-01-2009 |
20090124985 | SKIN TREATMENT DEVICE - A personal skin polishing or microdermabrasion device having a convenient form factor with a applicator attached to a contoured housing with a handle portion. The housing contains a battery, a cordless motor and a gear box to provide an appropriate rotational velocity to the output shaft that is coupled to the applicator. The applicator may be a foam material selected to cushion the skin from excessive abrasion to the particles in a personal care composition to be used with device, and to have a porosity that will enable the foam to interact with the particles and enhance the skin polishing effect. | 05-14-2009 |
20150037380 | APPLIED FILMS FOR SMOOTHING WRINKLES AND SKIN TEXTURE IMPERFECTIONS - A skin smoothing film made from a skin smoothing composition that comprises sodium silicate, polyvalent silicate and water. Moreover, the film may be made from a composition that has a contraction value of from about 30% to about 160%. The film thickness is from about 5 microns to about 50 microns, preferably from about 10 microns to about 40 microns, when applied. The standard deviation of the film over the area covered is less than about 30, preferably less than about 25. | 02-05-2015 |
Patent application number | Description | Published |
20090142794 | Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors - The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site. | 06-04-2009 |
20100040644 | METHODS FOR PREPARING IMMUNOGENIC CONJUGATES - Methods for making an immunogenic conjugate that includes a hapten or an antigen covalently linked to a carrier. The methods include reacting a first agent with a dihydrazide resulting in a hydrazine-modified first agent, wherein the first agent is a hapten, an antigen or a carrier; reacting a second agent with a benzaldehyde compound resulting in a benzaldehyde-modified second agent, wherein the second agent is a hapten, an antigen or a carrier, provided that the first agent or the second agent is a carrier; and reacting the hydrazine-modified first agent with the benzaldehyde-modified second agent resulting in an immunogenic conjugate comprising a hapten or an antigen covalently linked to a carrier via a hydrazone linkage. | 02-18-2010 |
20100119520 | MONOCLONAL ANTIBODIES THAT NEUTRALIZE ANTHRAX TOXINS - The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 05-13-2010 |
20100168012 | HUMAN CANCER THERAPY USING ENGINEERED MATRIX METALLOPROTEINASE-ACTIVATED ANTHRAX LETHAL TOXIN THAT TARGETS TUMOR VASCULATUTURE - The present invention provides methods for inhibiting tumor associated angiogenesis by administering a mutant protective antigen protein comprising a matrix metalloproteinase-recognized cleavage site in place of the native protective antigen furin-recognized site in combination with a lethal factor polypeptide comprising a protective antigen binding site. Upon cleavage of the mutant protective antigen by a matrix metalloproteinase, the lethal factor polypeptide is translocated into cancer and endothelial cells and inhibits tumor associated angiogenesis. | 07-01-2010 |
20100272757 | BACILLUS ANTHRACIS PROTECTIVE ANTIGEN NUCLEIC ACID SEQUENCES - The invention relates to improved methods of producing and recovering B. anthracisprotective antigen (PA), especially modified PA which is protease resistant, and to methods of using of these PAs or nucleic acids encoding these PAs for eliciting an immunogenic response in humans, including responses which provide protection against, or reduce the severity of, | 10-28-2010 |
20100330074 | USE OF SACCHARIDES CROSS-REACTIVE WITH BACILLUS ANTHRACIS SPORE GLYCOPROTEIN AS A VACCINE AGAINST ANTHRAX - Provided are immunogenic compositions and methods for eliciting an immune response against | 12-30-2010 |
20110280908 | MULTIMERIC PROTEIN TOXINS TO TARGET CELLS HAVING MULTIPLE IDENTIFYING CHARACTERISTICS - The present invention provides compositions comprising modified bacterial toxins and methods for using the modified bacterial toxins for targeting particular cell populations and for treating diseases. | 11-17-2011 |
20120009219 | BACILLUS ANTHRACIS PROTECTIVE ANTIGEN SEQUENCES - The invention relates to improved methods of producing and recovering | 01-12-2012 |
20120171196 | MONOCLONAL ANTIBODIES THAT NEUTRALIZE ANTHRAX TOXINS - The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 07-05-2012 |
20130058967 | RECOMBINANT MODIFIED BACILLUS ANTHRACIS PROTECTIVE ANTIGEN FOR USE IN VACCINES - The invention relates to improved methods of producing and recovering sporulation-deficient | 03-07-2013 |
20130273097 | USE OF SACCHARIDES CROSS-REACTIVE WITH BACILLUS ANTHRACIS SPORE GLYCOPROTEIN AS A VACCINE AGAINST ANTHRAX - Provided are immunogenic compositions and methods for eliciting an immune response against | 10-17-2013 |
20140314716 | PROTEASE-DEFICIENT BACILLUS ANTHRACIS - The invention relates to a | 10-23-2014 |
20140378654 | MUTATED ANTHRAX TOXIN PROTECTIVE ANTIGEN PROTEINS THAT SPECIFICALLY TARGET CELLS CONTAINING HIGH AMOUNTS OF CELL-SURFACE METALLOPROTEINASES OR PLASMINOGEN ACTIVATOR RECEPTORS - The present invention provides methods of specifically targeting compounds to cells overexpressing matrix metalloproteinases, plasminogen activators, or plasminogen activator receptors, by administering a compound and a mutant protective antigen protein comprising a matrix metalloproteinase or a plasminogen activator-recognized cleavage site in place of the native protective antigen furin-recognized cleavage site, wherein the mutant protective antigen is cleaved by a matrix metalloproteinase or a plasminogen activator overexpressed by the cell, thereby translocating into the cell a compound comprising a lethal factor polypeptide comprising a protective antigen binding site. | 12-25-2014 |
20150017153 | MONOCLONAL ANTIBODIES THAT NEUTRALIZE ANTHRAX TOXINS - The present invention relates to monoclonal antibodies that bind or neutralize anthrax lethal factor (LF), edema factor (EF), and/or protective antigen (PA). The invention provides such antibodies, fragments of such antibodies retaining anthrax toxin-binding ability, fully human or humanized antibodies retaining anthrax toxin-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention. | 01-15-2015 |
20150093412 | USE OF SACCHARIDES CROSS-REACTIVE WITH BACILLUS ANTHRACIS SPORE GLYCOPROTEIN AS A VACCINE AGAINST ANTHRAX - Provided are immunogenic compositions and methods for eliciting an immune response against | 04-02-2015 |